GSK India Market Share

The health food and beverage industry is a very delicate market and companies participating in these markets can not distinguish their products because everyone follows the same key characteristics, ie, stronger and more rigorous characteristics It Is difficult. Therefore, how does GSK make up the majority of the market space? In other words, 75% of the market share has room for discussion. In such markets, companies need to constantly build and bid for technical innovation to test and maintain their materials in the market, regardless of whether they are involved in their own commitment or not.

GlaxoSmithKline is the leader in the pharmaceutical industry, accounting for 7% of the global pharmaceutical market (GlaxoSmithKline, 2009). GSK's mission is to develop innovative drugs and products that will help millions of people around the world. As a firm with a strong scientific foundation, GSK has a record that turns research talent and research into a powerful and marketable medicine. GSK spends more than 300,000 pounds per hour for research and development (GlaxoSmithKline, 2009). Currently, one of the themes of the pharmaceutical industry is the acquisition of a small biotechnology company to understand knowledge by major pharmaceutical companies (The Economist, 2009). Therefore, innovation and acquisitions are the foundation of GSK's competitive strategy. For these reasons, GSK is the ideal candidate to refer to in this article.

In October 2003, UK-based pharmaceutical company GlaxoSmithKline (GSK) and India's largest pharmaceutical company Ranbaxy Laboratories announced drug development. According to the contract, the two companies separate research and development. GSK has a special commercial responsibility on a global scale, Ranbaxy is a leader in the huge Indian market and can be promoted in the United States and the EU with the consent of GSK. When Boots manufactures pharmaceuticals and cosmetics in India and sells them to European countries and the Middle East. Due to the brand names of Boots and Sun Pharma Boots, medicines can be sold in India and Asian countries. Next year's net income will increase to £ 950 million, an increase of £ 350 million over 2010